Latest News and Press Releases

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of NF1 Associated Plexiform Neurofibromas

Pasithea Therapeutics (Nasdaq: KTTA) will present to Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 25, 2026, 4:00 PM ET

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

Pasithea completes enrollment and dosing of first NF1 trial cohort; initial safety and efficacy data expected by Q1 2026.

Pasithea begins PAS-004 Phase 1/1b NF1 trial in Australia, with U.S. and S. Korea sites planned. First dosing set for Q2 2025. 48.5% R&D refund expected.

Pasithea Therapeutics (Nasdaq: KTTA) closes $5M public offering, adds $1.3M via warrant exercises, funding R&D for PAS-004 and other biotech innovations.

Pasithea Tx (Nasdaq: KTTA) will present updated Phase 1 data for MEK inhibitor PAS-004 in MAPK-driven cancers at ASCO 2025 on June 2 in Chicago.

Pasithea Therapeutics (KTTA) will present PAS-004 Phase 1 data at the 2025 CAGLA NeauxCancer Conference on March 28 in New Orleans.

Pasithea's PAS-004 Phase 1 trial advances to 22mg dose with no DLTs or rash, reinforcing its safety profile as a next-gen MEK inhibitor for NF1 and cancer.

Pasithea opens EU trial sites for PAS-004, doses Cohort 4, and plans interim safety data in Q1 2025.